Skip to main content
Isomer
  1. Home
  2. Automated
  3. NDF A-Z listing
  4. Lanreotide
L

Lanreotide

Subsidy Information and Financing Scheme

MAF

MSHL

Drug Guidance

No

Post-marketing information

No

Summary of Biologics

No

Active ingredient: Lanreotide

General information

Subsidy Information and Financing Scheme

[MAF] Lanreotide Prolonged-Release Solution For Injection In Pre-Filled Syringe 60 mg, 90 mg, 120 mg

  1. For the reduction of symptoms associated with carcinoid syndrome.

  2. For the improvement of symptoms associated with acromegaly.

  3. Treatment of acromegaly in patients with abnormal levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-

  4. after surgery and/or radiotherapy or in patients who require medical treatment.

  5. Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.

[MSHL] Lanreotide Prolonged-Release Solution For Injection In Pre-Filled Syringe 60 mg, 90 mg, 120 mg

  1. Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.

  2. For the reduction of symptoms associated with carcinoid syndrome.

  3. Treatment of acromegaly in patients with abnormal levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-

  4. after surgery and/or radiotherapy or in patients who require medical treatment.

  5. For the improvement of symptoms associated with acromegaly.

Legend

This section shows the following:

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

Legend list

Indicator

Legend

SDL

Standard Drug List

MAF

Medical Assistance Fund

SVL

Subsidised Vaccine List

MSHL

Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

Drug Guidance for Subsidy

Not Applicable

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Drug availability

Formulation

Public Healthcare Institution

Prolonged-Release Solution For Injection In Pre-Filled Syringe 60 mg

  1. Tan Tock Seng Hospital

Prolonged-Release Solution For Injection In Pre-Filled Syringe 90 mg

  1. Tan Tock Seng Hospital

Prolonged-Release Solution For Injection In Pre-Filled Syringe 120 mg

  1. National Cancer Centre

  2. National University Hospital

  3. Singapore General Hospital

  4. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated

monthly, please refer to HSA Infosearch for the most updated product information.

Subcutaneous

Back to top